Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 8, 2007 - Issue 16
Submit an article Journal homepage
140
Views
26
CrossRef citations to date
0
Altmetric
Review

Cutaneous leishmaniasis: therapeutic strategies and future directions

Mahreen Ameen Consultant Dermatologist, Royal Free Hospital, Department of Dermatology, London NW3 2QG, UK +44 2084726197; +44 2078302247; [email protected]
Pages 2689-2699 | Published online: 24 Oct 2007

Bibliography

  • DESJEUX P: Leishmaniasis: current situation and new perspectives. Comp. Immunol. Microbiol. Infect. Dis. (2004) 27:305-318.
  • YANIK M, GUREL MS, SIMSEK Z, KATI M: Psychological impact of cutaneous leishmaniasis. Clin. Exp. Dermatol. (2004) 29(5):464-467.
  • REITHINGER R, AADIL K, KOLACZINSKI J, MOHSEN M, HAMI S: The social impact of cutaneous leishmaniasis in Kabul, Afghanistan. Emerg. Infect. Dis. (2005) 11(4):634-636.
  • HERWALDT BL: Leishmaniasis. Lancet (1999) 354:1191-1199.
  • REED SG, SCOTT P: T-cell and cytokine responses in leishmaniasis. Curr. Opin. Immunol. (1993) 5:524-531.
  • BUXBAUM LU, DENISE H, COOMBS GH, ALEXANDER J, MOTTRAM JC, SCOTT P: Cysteine protease B of Leishmania mexicana inhibits host TH1 responses and protective immunity. J. Immunol. (2003) 171:3711-3717.
  • KELLY BL, STETSON DB, LOCKSLEY RM: Leishmania major LACK antigen is required for efficient vertebrate parasitization. J. Exp. Med. (2003) 198:1689-1698.
  • MEDEIROS ACR, RODRIGUES SS, ROSELINO AMF: Comparison of the specificity of PCR and the histopathological detection of Leishmania for the diagnosis of American cutaneous leishmaniasis. Braz. J. Med. Biol. Res. (2002) 35:421-424.
  • MURRAY HW, BERMAN JD, DAVIES CR, SARAVIA NG: Advances in leishmaniasis. Lancet (2005) 366:1561-1577.
  • DAVID C, DIMIER-DAVID L, VARGAS F, TORREZ M, DEDET JP: Fifteen years of cutaneous and mucocutaneous leishmaniasis in Bolivia: a retrospective study. Trans. R. Soc. Trop. Med. (1993) 73:339-345.
  • ANDRADE-NARVAEZ FJ, VARGAS-GONZALEZ A, CANTO-LARA SB et al.: Clinical picture of cutaneous leishmaniasis due to Leishmania (Leishmania) mexicana in the Yucatan peninsula, Mexico. Mem. Inst. Oswaldo Cruz (2001) 96:163-167.
  • MARSDEN PD: Mucosal leishmaniasis (‘espundia’). Trans. R. Soc. Trop. Med. Hyg. (1986) 80:859-876.
  • CUNNINGHAM ML, FAIRLAMB AH: Trypanothione reductase from Leishmania donovani. Purification, characterisation and inhibition by trivalent antimonials. Eur. J. Biochem. (1995) 4(2):460-468.
  • PATHAK MK, YI T: Sodium stibogluconate is a potent inhibitor of protein tyrosine phosphatases and augments cytokine responses in hemopoietic cell lines. J. Immnunol. (2001) 167(6):3391-3397.
  • BALLOU WR, MCCLAIN JB, GORDON DM et al.: Safety and efficacy of high-dose sodium stibogluconate therapy of American cutaneous leishmaniasis. Lancet (1987) 2(8549):13-16.
  • NAVIN TR, ARANA BA, ARANA FE, DEMERIDA AM, CASTILLO AL, POZUELOS JL: Placebo-controlled clinical trial of meglumine antimonate (glucantime) vs. localized controlled heat in the treatment of cutaneous leishmaniasis in Guatemala. Am. J. Trop. Med. Hyg. (1990) 42:43-50.
  • ARANA BA, NAVIN TR, ARANA FE, BERMAN JD, ROSENKAIMER F: Efficacy of a short course (10 days) of high-dose meglumine antimoniate with or without interferon-γ in treating cutaneous leishmaniasis in Guatemala. Clin. Infect. Dis. (1994) 18(3):381-384.
  • WORTMANN G, MILLER RS, OSTER C, JACKSON J, ARONSON N: A randomized, double-blind study of the efficacy of a 10- or 20-day course of sodium stibogluconate for the treatment of cutaneous leishmaniasis in United States military personnel. Clin. Infect. Dis. (2002) 35(3):261-267.
  • SUNDAR S, MORE DK, SINGH MK et al.: Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin. Infect. Dis. (2000) 31:1104-1107.
  • CARTER KC, SUNDAR S, SPICKETT C, PEREIRA OC, MULLEN AB: The in vivo susceptibility of Leishmania donovani to sodium stibogluconate is drug specific and can be reversed by inhibiting glutathione biosynthesis. Antimicrob. Agents Chemother. (2003) 47(5):1529-1535.
  • CARTER KC, HUTCHISON S, HENRIQUEZ FL et al.: Resistance of Leishmania donovani to sodium stibogluconate is related to the expression of host and parasite g-glutamylcysteine synthetase. Antimicrob. Agents chemother. (2006) 50(1):88-95.
  • MOORE E, O'FLAHERTY D, HEUVELMANS H et al.: Comparison of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya. Bull. World Health Organ. (2001) 79(5):388-393.
  • FREZARD F, MICHALICK MS, SOARES CF, DEMICHELI C: Novel methods for the encapsulation of meglumine antimoniate into liposomes. Braz. J. Med. Biol. Res. (2000) 33(7):841-846.
  • BERMAN JD, WYLER DJ: An in vitro model for investigation of chemotherapeutic agents in leishmaniasis. J. Infect. Dis. (1980) 142:83-86.
  • NACHER M, CARME B, SAINTE MARIE D et al.: Influence of clinical presentation on the efficacy of a short course of pentamidine in the treatment of cutaneous leishmaniasis in French Guiana. Ann. Trop. Med. Parasitol. (2001) 95(4):331-336.
  • SOTO-MANCIPE J, GROGL M, BERMAN JD: Evaluation of pentamidine for the treatment of cutaneous leishmaniasis in Colombia. Clin. Infect. Dis. (1993) 16(3):417-425.
  • ANDERSON EM, CRUZ-SALDARRIAGA M, LLANOS-CUENTAS A et al.: Comparison of meglumine antimoniate and pentamidine for Peruvian cutaneous leishmaniasis. Am. J. Trop. Med. Hyg. (2005) 72(2):133-137.
  • ROUSSEL M, NACHER M, FREMONT G et al.: Comparison between one and two injections of pentamidine isethionate, at 7 mg/kg in each injection, in the treatment of cutaneous leishmanaisis in French Guiana. Am. Trop. Med. Parasitol. (2006) 100(4):307-314.
  • LAI A, FAT EJSK, VREDE MA, SOETOSENOJO RM, LAI A, FAT RFM: Pentamidine, the drug of choice for the treatment of cutaneous leishmaniasis in Surinam. Int. J. Dermatol. (2002) 41:796-800.
  • MISHRA M, BISWAS UK, JHA DN, KHAN AB: Amphoericin versus pentamidine in antimony-unresponsive kala-azar. Lancet (1992) 340:1256-1257.
  • YARDLEY V, CROFT SL: Activity of liposomal amphotericin B against experimental cutaneous leishmaniasis. Antimicrob. Agents Chemother. (1997) 41(4):752-756.
  • SOLOMON M, BAUM S, BARZILAI A et al.: Liposomal amphotericin B in comparison to sodium stibogluconate for cutaneous infection due to Leishmania braziliensis. J. Am. Acad. Dermatol. (2007).
  • ALRAJHI AA, IBRAHIM EA, DE VOL EB, KHAIRAT M, FARIS RM, MAGUIRE JH: Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N. Engl. J. Med. (2002) 346:891-895.
  • WEINRAUCH L, LIVSHIN R, EL-ON J: Ketoconazole in cutaneous leishmaniasis. Br. J. Dermatol. (1987) 117(5):666-668.
  • SAENZ RE, PAZ H, BERMAN JD: Efficacy of ketoconazole against Leishmania braziliensis panamensis cutaneous leishmaniasis. Am. J. Med. (1990) 89(2):147-155.
  • NAVIN TR, ARANA BA, ARANA FE, BERMAN JD, CHAJON JF: Placebo-controlled clinical trial of sodium stibogluconate (pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. J. Infect. Dis. (1992) 165:528-534.
  • MOMENI AZ, JALAYER T, EMAMJOMEH M et al.: Treatment of cutaneous leishmaniasis with itraconazole. Arch. Dermatol. (1996) 132:784-786.
  • NISSIRI-KASHANI M, FIROOZ A, KHAMESIPOUR A et al.: A randomized double-blind, placebo-controlled clinical trial of itraconazole in the treatment of cutaneous leishmaniasis. J. Eur. Acad. Dermatol. Venereol. (2005) 19:80-83.
  • AL-ABDELY HM, GRAYBILL JR, LOEBENBERG D, MELBY PC: Efficacy of the triazole SCH 56592 against Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous and visceral leishmaniases. Antimicrob. Agents Chemother. (1999) 43:2910-2914.
  • NELSON DJ, LAFON SW, TUTTLE JV et al.: Allopurinol ribonucleoside as an antileishmanial agent. Biological effects, metabolism and enzymatic phosphorylation. J. Biol. Chem. (1979) 254(22):11544-11549.
  • VELEZ I, AGUDELO S, HENDRICKX E et al.: Inefficacy of allopurinol as monotherapy for Colombian cutaneous leishmaniasis. Ann. Intern. Med. (1997) 126:232-236.
  • MARTINEZ S, GONZALEZ M, VERNAZA ME: Treatment of cutaneous leishmaniasis with allopurinol and stibogluconate. Clin. Infect. Dis. (1997) 24:165-169.
  • MOMENI A, AMINJAVAHERI M: Treatment of recurrent cutaneous leishmaniasis. Int. J. Dermatol. (1995) 34:129-133.
  • ESFANDIARPOUR I, ALAVI A: Evaluating the efficacy of allopurinol and meglumine antimoniate (glucantime) in the treatment of cutaneous leishmaniasis. Int. J. Dermatol. (2002) 41(8):521-524.
  • SCHMIDT-OTT R, KLENNER T, OVERATH P, AEBISCHER T: Topical treatment with hexadecylphosphocholine (miltex) efficiently reduces parasite burden in experimental cutaneous leishmaniasis. Trans. R. Soc. Med. Hyg. (1999) 93:85-90.
  • ESCOBAR P, MATU S, MARQUES C, CROFT SL: Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH(3) (edelfosine) and amphotericin B. Acta Trop. (2002) 81:151-157.
  • JHA TK, SUNDAR S, THAKUR CP et al.: Miltefosine, an oral agent for the treatment of Indian visceral leishmaniasis. N. Engl. J. Med. (1999) 341:1795-1800.
  • SUNDAR S, JHA TK, THAKUR CP et al.: Oral miltefosine for Indian visceral leishmaniasis. N. Engl. J. Med. (2002) 347:1739-1746.
  • BHATTACHARYA SK, JHA TK, SUNDAR S et al.: Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India. Clin. Infect. Dis. (2004) 38:217-221.
  • SOTO J, TOLEDO J, GUTIERREZ P et al.: Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin. Infect. Dis. (2001) 33:57-61.
  • SOTO J, ARANA BA, TOLEDO J et al.: Miltefosine for New world cutaneous leishmaniasis. Clin. Infect. Dis. (2004) 38:1266-1272.
  • SOTO J, TOLEDO JT: Oral miltefosine to treat new world cutaneous leishamaniasis. Lancet Infect. Dis. (2007) 7(1):7.
  • ZERPA O, BLANCO B, KANNEE C et al.: Treatment of diffuse cutaneous leishmaniasis with miltefosine: a case report. Int. J. Dermatol. (2006) 45(6):751-753.
  • UZUN S, DURDU M, CULHA G, ALLAHVERDIYEV AM, MEMISOGLU HR: Clinical features, epidemiology and efficacy and safety of intralesional antimony treatment of cutaneous leishmaniasis: recent experience in Turkey. J. Parasitol. (2004) 90(4):853-859.
  • FARIS RM, JARALLAH JS, KHOJA TA, AL-YAMANI MJ: Intralesional treatment of cutaneous leishmaniasis with sodium stibogluconate antimony. Int. J. Dermatol. (1993) 32(8):610-612.
  • TALLAB TM, BAHAMDAM KA, MIRDAD S et al.: Cutaneous leishmaniasis: schedules for intralesional treatment with sodium stibogluconate. Int. J. Deramtol. (1996) 35(8):594-597.
  • THAKUR CP, KANYOK TP, PANDEY AK et al.: A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone in the treatment of visceral leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. (2000) 94:429-431.
  • MAAROUF M, LAWRENCE F, CROFT SL, ROBERT-GERO M: Ribosomes of Leishmania are a target for the aminoglycosides. Parasitol. Res. (1995) 81:421-425.
  • EL-ON J, MESSER G: Leishmania major: antileishmanial activity of methylbenzethonium chloride. Am. J. Trop. Med. Hyg. (1986) 35(6):1110-1116.
  • EL-ON J, HALEVY S, GRUNWALD MH, WEINRAUCH L: Topical treatment of Old World cutaneous leishmaniasis caused by Leishmania major: a double-blind control study. J. Am. Acad. Dermatol. (1992) 27:227-231.
  • ASILIAN A, JALAYER T, WHITWORTH JA, GHASEMI RL, NILFOROOSHZADEH M, OLLIARO P: A randomized placebo-controlled trial of a two-week regimen of aminosidine (paromomycin) ointment for treatment of cutaneous leishmaniasis in Iran. Am. J. Trop. Med. Hyg. (1995) 53(6):648-651.
  • EL-ON J, CAWICH F, EVANS DA, WEINRAUCH: Topical treatment of cutaneous leishmaniasis in Belize: in vitro and in vivo studies with Leishmania mexicana. Int. J. Parasitol. (1993) 23(1):121-127.
  • ARANA BA, MENDOZA CE, RIZZO NR KROEGER A: Randomized controlled double-blind trial of topical treatment of cutaneous leishmaniasis with paromomycin plus methylbenzethonium chloride ointment in Guatemala. Am. J. Trop. Med. Hyg. (2001) 65(5):466-470.
  • HARMS G, CHEHADE AK, DOUBA M et al.: A randomized trial comparing a pentavalent antimonial drug and recombinant interferon-g in the local treatment of cutaneous leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. (1991) 85(2):214-216.
  • SANTOS JB, DE JESUS AR, MACHADO PR et al.: Antimony plus recombinant human granulocyte-macrophage colony-stimulating factor applied topically in low doses enhances healing of cutaneous leishmaniasis ulcers: a randomized, double-blind placebo-controlled study. J. Infect. Dis. (2004) 190(10):1793-1796.
  • BUATES S, MATLASHEWSKI G: Treatment of experimental leishmaniasis with the immunomodulators imiquimod and S-28463: efficacy and mode of action. J. Infect. Dis. (1999) 179:1485-1494.
  • AREVALO I, WARD B, MILLER R et al.: Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator. Clin. Infect. Dis. (2001) 33:1847-1851.
  • MIRANDA-VERASTEGUI C, LLANOS-CUENTAS A, AREVALO I, WARD BJ, MATLASHEWSKI G: Randomized double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru. Clin. Infect. Dis. (2005) 40:1395-1403.
  • FIROOZ A, KHAMESIPOUR A, GHOORCHI MH et al.: Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis. Arch. Dermatol. (2006) 142:1575-1580.
  • VELASCO-CASTREJON O, WALTON BC, RIVAS-SANCHEZ B et al.: Treatment of cutaneous leishmaniasis with localized current field (radio frequency) in Tabasco, Mexico. Am. J. Trop. Med. Hyg. (1997) 57(3):309-312.
  • REITHINGER R, MOHSEN M, WAHID M et al.: The efficacy of thermotherapy to treat cutaneous leishmaniasis caused by Leishmania tropica in Kabul, Afghanistan: a randomized controlled trial. Clin. Infect. Dis. (2005) 40:1148-1155.
  • EL DAROUTI MA, RUBAIE SM: Cutaneous leishmaniasis: treatment with combined crotherapy and intralesional stibogluconate injection. Int. J. Dermatol. (1990) 29(1):56-59.
  • AL MAJALI O, ROUTH HB, ABULOHAM O, BHOWMISK KR, MUHSEN M, HEBEHEBA H: A 2-year study of liquid nitrogen therapy in cutaneous leishmaniasis. Int. J. Dermatol. (1997) 36(6):460-462.
  • GUREI MS, TATLI N, OZBILGE H et al.: Efficacy of cryotherapy and intralesional pentostam in treatment of cutaenous leishmaniasis. J. Egypt Soc. Parasitol. (2000) 30(1):169-176.
  • ALVAR J, CANAVATE C, GUTIERREZ-SOLAR B et al.: Leishmania and human immunodeficiency virus coinfection: the first ten years. Clin. Microbiol. Rev. (1997) 10(2):298-319.
  • PASQUAU F, ENA J, SANCHEZ R et al.: Leishmaniasis as an opportunistic infection in HIV-infected patients: determinants of relapse and mortality in a collaborative study of 228 episodes in a Mediterranean region. Eur. J. Clin. Micrbiol. Infect. Dis. (2005) 24(6):411-418.
  • COUPPIE P, CLYTI E, SOBESKY M et al.: Comparative study of cutaneous leishmaniasis in human immunodeficiency virus (HIV)-infected patients and non-HIV-infected patients in French Guiana. Br. J. Dermatol. (2004) 151(6):1165-1171.
  • BARAT C, ZHAO C, OUELLETTE M, TREMBLAY MJ: HIV-1 replication is stimulated by sodium stiboluconate, the therapeutic mainstay in the treatment of leishmaniasis. J. Infect. Dis. (2007) 195:236-245.
  • SINDERMANN H, ENGEL KR, FISCHER C, BOMMER W: Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection. Clin. Infect. Dis. (2004) 39:1520-1523.
  • CONVIT J, ULRICH M, POLEGRE MA et al.: Therapy of Venezuelan patients with severe mucocutaneous or early lesions of diffuse cutaneous leishmaniasis with a vaccine containing pasteurized Leishmania promastigotes and bacillus Calmette-Guerrin – preliminary report. Mem. Inst. Oswaldo Cruz. (2004) 91(1):57-62.
  • CONVIT J, ULRICH M, ZERPA O et al.: Immunotherapy of American cutaneous leishmaniasis in Venezuela during the period 1990 – 1999. Trans. R. Soc. Trop. Med. Hyg. (2003) 97(4):469-472.
  • REQUENA JM, IBORRA S, CARRION J, ALONSO C, SOTO M: Recent advances in vaccines for leishmaniasis. Expert Opin. Biol. Ther. (2004) 4:1505-1517.
  • IVENS AC, PEACOCK CS, WORTHEY EA et al.: The genome of the kinetoplastid parasite Leishmania major. Science (2005) 309:436-442.
  • STOBER CB, LANGE UG, ROBERTS MT et al.: From genome to vaccines for leishmaniasis: screening 100 novel vaccine candidates against murine Leishmania major infection. Vaccine (2006) 24(14):2602-2016.
  • JONES TC, JOHNSON WD, BARRETO AC et al.: Epidemiology of American leishmaniasis due to Leishmania braziliensis braziliensis. J. Infect. Dis. (1987) 156:73-83.
  • WALTON BC, VALVERDE L: Racial differences in espundia. Ann. Trop. Med. Parasitol. (1979) 73:23-29.
  • CABRERA M, SHAW MA, SHRAPLES C et al.: Polymorphism in TNF genes associated with mucocutaneous leishmaniasis. J. Exp. Med. (1995) 182(5):1259-1264.
  • OLIVO-DIAZ A, DEBAZ H, ALAEZ C et al.: Role of HLA class II alleles in susceptibility to and protection from localized cutaneous leishmaniasis. Hum. Immunol. (2004) 65(3):255-261.
  • KAMALI-SARVESTANI E, RASOULI M, MORTAZAVI H, GHARESI-FARD B: Cytokine gene polymorphisms and susceptibility to cutaneous leishmaniasis in Iranian patients. Cytokine (2006) 35(3-4):159-165.
  • BOURREAU E, PREVOT G, GARDON J, PRADINAUD R, LAUNOIS P: High intralesional interleukin-10 messenger RNA expression in localized cutaneous leishmaniasis is associated with unresponsiveness to treatment. J. Infect. Dis. (2001) 184:1628-1630.
  • RODRIGUEZ N, BAILEY BN, MARTIN MB et al.: Radical cure of experimental cutaneous leishmaniasis by the biphosphonate pamidronate. J. Infect. Dis. (2002) 186:138-140.
  • SEIFERT K, MATU S, PEREZ-VICTORIA FJ et al.: Characterization of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine). Int. J. Antimicrob. Agents (2003) 22:380-387.
  • BRYCESON A: A policy for leishmaniasis with respect to the prevention and control of drug resistance. Trop. Med. Int. Health (2001) 6:928-934.
  • SEIFERT K, CROFT SL: In vitro and in vivo intercations between miltefosine and other antileishmanial drugs. Antimicrob. Agents Chemother. (2006) 50:73-79.
  • KROEGER A, VILLEGAS AVILA E, MORISON L: Insecticide impregnated curtains to control domestic transmission of cutaneous leishmaniasis in Venezuela: cluster randomised trial. BMJ (2002) 325:810-813.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.